Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial

AIMS: Empagliflozin reduces cardiovascular death (CVD) or heart failure hospitalization (HHF) in patients with heart failure and preserved ejection fraction (HFpEF). Treatment effects and safety in relation to resting heart rate (RHR) have not been studied. METHODS AND RESULTS: The interplay of RHR...

Descripción completa

Detalles Bibliográficos
Autores principales: Böhm, Michael, Butler, Javed, Mahfoud, Felix, Filippatos, Gerasimos, Ferreira, João Pedro, Pocock, Stuart J., Slawik, Jonathan, Brueckmann, Martina, Linetzky, Bruno, Schüler, Elke, Wanner, Christoph, Zannad, Faiez, Packer, Milton, Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Focused Issue on Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828798/
https://www.ncbi.nlm.nih.gov/pubmed/36087309
http://dx.doi.org/10.1002/ejhf.2677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828798/
https://www.ncbi.nlm.nih.gov/pubmed/36087309
http://dx.doi.org/10.1002/ejhf.2677

Ejemplares similares